HealthDay News – For women with bacterial vaginosis, Lactobacillus crispatus CTV-05 (Lactin-V) after vaginal metronidazole results in a lower incidence of recurrence at 12 weeks, according to a study published in the May 14 issue of the New England Journal of Medicine.
Craig R. Cohen, MD, from the University of California in San Francisco, and colleagues conducted a randomized phase 2b trial to examine the ability of Lactin-V to prevent bacterial vaginosis recurrence. Women aged 18 to 45 years with a diagnosis of bacterial vaginosis who had completed a course of vaginal metronidazole gel were randomly assigned in a 2:1 ratio to receive vaginally administered Lactin-V or placebo for 11 weeks (152 and 76 participants, respectively).
Overall, 88 and 84% of the women in the Lactin-V and placebo groups could be assessed for the primary outcome. The researchers found that recurrence of bacterial vaginosis by week 12 occurred in 30 and 45% of participants in the Lactin-V and placebo groups, respectively, in the intention-to-treat analysis (risk ratio after multiple imputation for missing responses, 0.66). For recurrence by week 24, the risk ratio was 0.73. L. crispatus CTV-05 was detected in 79% of participants in the Lactin-V group at the 12-week visit.
“The use of Lactin-V after treatment with vaginal metronidazole for bacterial vaginosis resulted in a significantly lower incidence of recurrence of bacterial vaginosis at 12 weeks than placebo, and the benefit appeared to persist through week 24,” the authors write.